Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm

doi:10.1016/S0140-6736(97)80083-9

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

W A Stack
, S D Mann
, A J Roy
, P Heath
, M Sopwith
, J Freeman
, G Holmes
, R Long
, A Forbes
, M A Kamm

Research output: Contribution to journal › Article › peer-review

422 Citations (Scopus)

Abstract

Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.

Original language	English
Pages (from-to)	521-524
Number of pages	4
Journal	The Lancet
Volume	349
Issue number	9051
DOIs	https://doi.org/10.1016/S0140-6736(97)80083-9
Publication status	Published - 22 Feb 1997

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adolescent
Adult
Aged
Antibodies
C-Reactive Protein
Crohn Disease
Double-Blind Method
Glycoproteins
Humans
Middle Aged
Placebos
Remission Induction
Tumor Necrosis Factor-alpha

Access to Document

10.1016/S0140-6736(97)80083-9

Cite this

@article{a3a1c27d1a934f5f80a52d30d8adcdeb,

title = "Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease",

abstract = "Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.",

keywords = "Adolescent, Adult, Aged, Antibodies, C-Reactive Protein, Crohn Disease, Double-Blind Method, Glycoproteins, Humans, Middle Aged, Placebos, Remission Induction, Tumor Necrosis Factor-alpha",

author = "Stack, \{W A\} and Mann, \{S D\} and Roy, \{A J\} and P Heath and M Sopwith and J Freeman and G Holmes and R Long and A Forbes and Kamm, \{M A\}",

year = "1997",

month = feb,

day = "22",

doi = "10.1016/S0140-6736(97)80083-9",

language = "English",

volume = "349",

pages = "521--524",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9051",

}

TY - JOUR

T1 - Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

AU - Stack, W A

AU - Mann, S D

AU - Roy, A J

AU - Heath, P

AU - Sopwith, M

AU - Freeman, J

AU - Holmes, G

AU - Long, R

AU - Forbes, A

AU - Kamm, M A

PY - 1997/2/22

Y1 - 1997/2/22

N2 - Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.

AB - Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies

KW - C-Reactive Protein

KW - Crohn Disease

KW - Double-Blind Method

KW - Glycoproteins

KW - Humans

KW - Middle Aged

KW - Placebos

KW - Remission Induction

KW - Tumor Necrosis Factor-alpha

U2 - 10.1016/S0140-6736(97)80083-9

DO - 10.1016/S0140-6736(97)80083-9

M3 - Article

C2 - 9048788

SN - 0140-6736

VL - 349

SP - 521

EP - 524

JO - The Lancet

JF - The Lancet

IS - 9051

ER -